Patents Issued in February 25, 2016
-
Publication number: 20160052937Abstract: A compound represented by formula (I): wherein R is a methyl group or the like, R1 is a fluorine atom or the like, R2 is a hydrogen atom or a fluorine atom, R3 is a hydrogen atom, R4 is an ethyl group or the like, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 20, 2015Publication date: February 25, 2016Inventors: Mamoru Takaishi, Nobuhiro Sato, Takafumi Motoki, Tomoyuki Shibuguchi
-
Publication number: 20160052938Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R7, A, V, W, X, Y, n, r and q are as defined herein, their use as inhibitors of MDM2-p53 interaction, pharmaceutical compositions which contain compounds of this kind, their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases, and synthetic intermediates.Type: ApplicationFiled: August 20, 2015Publication date: February 25, 2016Inventors: Juergen RAMHARTER, Joachim BROEKER, Annika GILLE, Andreas GOLLNER, Manuel HENRY, Nina KERRES, Harald WEINSTABL
-
Publication number: 20160052939Abstract: The present invention is directed to compounds of Formula I: wherein X is N or CR1; Y is N or CR2; R1 is H, alkoxy, halo, triazolyl, pyrimidinyl, oxazolyl, isoxazole, oxadiazolyl, or pyrazolyl; R2 is H, alkyl, alkoxy, or halo; Z is NH or O; R3 is H, alkyl, alkoxy, halo, or triazolyl; R4 is H or alkyl; or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; R5 is pyridyl, pyrazinyl, or pyrimidinyl, wherein the pyridyl, pyrazinyl, or pyrimidinyl is optionally substituted with halo or alkyl; and n is 1 or 2. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.Type: ApplicationFiled: March 12, 2014Publication date: February 25, 2016Applicant: Janssen Pharmaceutica NVInventors: Christine F. GELIN, Terry P. LEBOLD, Brock T. SHIREMAN, Jeannie M. ZIFF
-
Publication number: 20160052940Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.Type: ApplicationFiled: October 29, 2015Publication date: February 25, 2016Applicant: GENENTECH, INC.Inventors: ANTHONY ESTRADA, LITING DONG, KEVIN X. CHEN, PAUL GIBBONS, MALCOLM HUESTIS, TERRY KELLAR, WEN LIU, CHANGYOU MA, JOSEPH LYSSIKATOS, ALAN OLIVERO, SNAHEL PATEL, DANIEL SHORE, MICHAEL SIU
-
Publication number: 20160052941Abstract: A cocrystal having the formula LiX.aM, or a solvate or hydrate thereof, wherein X is a conjugate base of an organic acid, M is a neutral organic molecule, and a is from 0.5 to 4, pharmaceutical compositions comprising such cocrystals, cocrystal solvates, or cocrystal hydrates, and methods of preparing such cocrystals, cocrystal solvates, or cocrystal hydrates, and such pharmaceutical compositions.Type: ApplicationFiled: April 18, 2014Publication date: February 25, 2016Applicant: University of South FloridaInventors: Michael John ZAWOROTKO, Naga DUGGIRALA, Adam John SMITH, Roland Douglas SHYTLE
-
Publication number: 20160052942Abstract: The invention provides compositions and methods for mass spectrometric (MS), organic synthesis, and applications of organo-trifluoroborate, for example, as mass tags for use in negative ion mode. When subject to MS fragmentation, organo-trifluoroborates preferentially undergo neutral losses of hydrogen fluoride (HF) or boron trifluoride (BF3) molecules, transferring the negative charge to the rest of the molecule. Such a fragmentation pattern is used to detect and quantitate analytes of interest after derivatization with organo-trifluoroborates.Type: ApplicationFiled: March 26, 2014Publication date: February 25, 2016Inventor: Yumei Huang
-
Publication number: 20160052943Abstract: A method for preparing oxyborane compounds of formula (I): using carbon dioxide, and the use of the oxyborane compounds obtained in this way for preparing methane derivatives, in particular oxygenated, halogenated or amino derivatives of methane. The methane derivatives obtained in this way can then be used in the production of vitamins, pharmaceutical products, glues, acrylic fibres and synthetic leathers, pesticides, and fertilisers, for example. Also provided is a method for producing vitamins, pharmaceutical products, glues, acrylic fibres, synthetic leathers, pesticides, and fertilisers, for example, including a step of preparing methane derivatives, in particular oxygenated, halogenated or amino derivatives of methane, from oxyborane compounds obtained by the method according to the invention. Further provided is a method of preparing labelled oxyborane compounds and the use of same.Type: ApplicationFiled: April 1, 2014Publication date: February 25, 2016Inventors: Thibault CANTAT, Christophe GOMES, Enguerrand BLONDIAUX, Olivier JACQUET
-
Publication number: 20160052944Abstract: The present invention relates to a manufacturing method for a liquid high-purity glycerin derivative-modified silicone, the method comprising: a step of adding, to a mixture containing a glycerin derivative-modified silicone and impurities, an organic wax having affinity with the impurities and having a higher melting point than the glycerin derivative-modified silicone, melting and mixing while heating, and introducing the impurities into the melted organic wax; a step of obtaining a solidified product of the organic wax by cooling the organic wax; and a step of performing solid-liquid phase separation on the glycerin derivative-modified silicone and the solidified product of the organic wax. With the present invention, it is possible to provide a useful method for stably producing a high-purity glycerin derivative-modified silicone on a commercial scale.Type: ApplicationFiled: December 26, 2013Publication date: February 25, 2016Inventors: Seiki Tamura, Sayuri Sawayama, Seiji Hori
-
Publication number: 20160052945Abstract: The present invention relates to a method for silylating 2-amino-1,3,5-triazines of the general formula (I) in which R1 and R2 are each independently hydrogen, hydroxyl, NH2, NHR3, NR32, NO2, NHCOR3, C1- to C20 -alkyl, C1- to C20-hydroxyalkyl, C2- to C20-alkenyl, C1- to C20-alkoxy, aryl or aryloxy optionally substituted with C1- to C8-alkyl and R3 is C1- to C20-alkyl, C3- to C12-cycloalkyl, C4 to C30-alkylcycloalkyl, aryl optionally substituted with C1- to C8-alkyl, with silanes, by reacting silanes of the general formula (ID X—SiH(R4R5) ??(II), in which X is fluorine, chlorine, bromine or iodine R4 and R5 are each independently C1- to C20-alkyl, C1- to C20-hydroxyalkyl, C1- to C20-haloalkyl, C2- to C20-alkenyl, C1- to C20-alkoxy, aryl or aryloxy optionally substituted with C1- to C8-alkyl, in the presence of a base.Type: ApplicationFiled: April 1, 2014Publication date: February 25, 2016Inventors: Alexander KÖNIG, Rebekka VON BENTEN, Jens AßMANN, Edwin KROKE, Sandra JÄHNIGEN, Anke SCHWARZER
-
Publication number: 20160052946Abstract: The present invention discloses a composition comprising a compound of formula I and a deuterated solvent. The deuterated solvent is miscible with water in any proportion at a temperature of 20 to 25° C. and comprises less than 5% residual 1H-isotopes. The concentration of the compound of formula I may advantageously be determined by 1H-QNMR. Methods of production of the composition and salts of compounds of formula I, as well as related analogs and novel reagents and intermediates for the production thereof, are also described.Type: ApplicationFiled: April 30, 2014Publication date: February 25, 2016Applicant: Pethmark ABInventors: David Wensbo Posaric, Karl-Erik Berquist
-
Publication number: 20160052947Abstract: Provided are a water-soluble triarylphosphine for a palladium catalyst, which has high selectivity in a telomerization reaction and can be recovered with efficiency, an ammonium salt thereof, and a method for efficiently producing the same. Specifically, provided are bis(6-methyl-3-sulphophenyl)phenylphosphine; a bis(6-methyl-3-sulphonatophenyl)phenylphosphine diammonium salt obtained by reacting the phosphine with a tertiary amine having a total of 3 to 27 carbon atoms in groups bonded to one nitrogen atom; and a method for producing the same.Type: ApplicationFiled: March 26, 2014Publication date: February 25, 2016Applicants: KURARAY CO., LTD., HOKKO CHEMICAL INDUSTRY CO., LTD.Inventors: Eriko HONDA, Tatsuya YOSHIKAWA, Tomoaki TSUJI, Hitoshi KOIZUMI, Kyoko SUGITA, Nobumichi KUMAMOTO
-
Publication number: 20160052948Abstract: Provided are a water-soluble triarylphosphine for a palladium catalyst, which has high selectivity in a telomerization reaction and is easily recovered with efficiency, an ammonium salt thereof, and a method for efficiently producing the same. Specifically, provided are bis(6-methyl-3-sulphophenyl)(2-methylphenyl)phosphine; a bis(6-methyl-3-sulphonatophenyl)(2-methylphenyl)phosphine diammonium salt obtained by reacting the phosphine with a tertiary amine having a total of 3 to 27 carbon atoms in groups bonded to one nitrogen atom; and a method for producing the same.Type: ApplicationFiled: March 26, 2014Publication date: February 25, 2016Applicants: KURARAY CO., LTD., HOKKO CHEMICAL INDUSTRY CO., LTD.Inventors: Eriko HONDA, Tatsuya YOSHIKAWA, Tomoaki TSUJI, Hitoshi KOIZUMI, Kyoko SUGITA, Nobumichi KUMAMOTO
-
Publication number: 20160052949Abstract: Solid base catalysts and their use for the base-catalyzed depolymerization (BCD) of lignin to compounds such as aromatics are presented herein. Exemplary catalysts include layered double hydroxides (LDHs) as recyclable, heterogeneous catalysts for BCD of lignin.Type: ApplicationFiled: August 4, 2015Publication date: February 25, 2016Inventors: Gregg T. BECKHAM, Mary J. BIDDY, Jacob S. KRUGER, Stephen C. CHMELY, Matthew STURGEON
-
Publication number: 20160052950Abstract: A process for preparing a composition (C1) represented by the formula (I): HO—CH2—(CHOH)n—CH2—O-(G)x-H, in which G represents the remainder of a reducing sugar, n is an integer equal to 2, 3 or 4 and x, which indicates the mean degree of polymerization of the remainder G, represents a decimal number greater than 1 and less than or equal to 5, characterized in that the process includes at least one step a) of reacting a polyol of formula (A1): HO—CH2—(CHOH)n—CH2—OH, in which n is an integer equal to 2, 3 or 4, with a reducing sugar of formula (II): HO-G-H, in which G represents the remainder of a reducing sugar, in the presence of an acid catalyst (Ca), and in that the acid catalyst (Ca) is chosen from phosphorous acid, phosphoric acid and polyphosphoric acid.Type: ApplicationFiled: February 4, 2014Publication date: February 25, 2016Inventors: Andre BENATTAR, Andrey BONNARDEL, Jerome GUILBOT, Sebastien KERVERDO, Herve ROLLAND, Guy TABACCHI
-
Publication number: 20160052951Abstract: Provided herein are methods of preparing macrolides by the coupling of an eastern and western half, followed by macrocyclization, to provide macrolides, including both known and novel macrolides. Intermediates in the synthesis of macrolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using the inventive macrolides are also provided. A general diastereoselective aldol methodology used in the synthesis of the western half is further provided.Type: ApplicationFiled: April 4, 2014Publication date: February 25, 2016Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGEInventors: Andrew G. Myers, Ian Bass Seiple, Ziyang Zhang
-
Publication number: 20160052952Abstract: In one aspect, the invention relates to substituted gemcitabine aryl amide analogs, derivatives thereof, and related compounds; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating viral disorders and disorders of uncontrolled cellular proliferation using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: ApplicationFiled: March 15, 2014Publication date: February 25, 2016Inventor: Zucai SUO
-
Publication number: 20160052953Abstract: Provided herein are formulations, methods and substituted 2?-chloro aminopyrimidinone and pyrimidine dione compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as methods and intermediates for synthesis of substituted 2?-chloro aminopyrimidinone and pyrimidine dione compounds.Type: ApplicationFiled: August 19, 2015Publication date: February 25, 2016Inventors: Michael O'Neil Hanrahan Clarke, Richard L. Mackman, Dustin Siegel
-
Publication number: 20160052954Abstract: The invention relates to compounds and methods useful in detection and therapy of HPV-associated diseases. The invention is based on the elucidation of a mechanism by which replication of HPVs occurs in naturally infected tissues and cells. Moreover it is based on the identification of distinct epigenetic changes of the viral genome in infected cells that allows promotion of the affected cells to precancerous and cancerous cells. The invention therefore provides methods of diagnosing neoplasias and their precursor lesions as well as methods of preventing the development of malignancies or inhibiting tumor growth.Type: ApplicationFiled: August 31, 2015Publication date: February 25, 2016Applicant: Ruprecht-Karls-Universitat HeidelbergInventors: Magnus Von Knebel Doeberitz, Svetlana Vinokurova
-
Publication number: 20160052955Abstract: Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structure and are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.Type: ApplicationFiled: April 15, 2014Publication date: February 25, 2016Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCHInventors: Minkui LUO, Weihong ZHENG
-
Publication number: 20160052956Abstract: The invention relates to compounds of Formula A: or a salt, solvate, or hydrate thereof. The compounds of formula A are TGR5 modulators useful for the treatment of disease.Type: ApplicationFiled: August 1, 2014Publication date: February 25, 2016Inventor: Roberto Pellicciari
-
Publication number: 20160052957Abstract: This disclosure relates to progesterone derivatives and uses related thereto. In certain embodiments, the disclosure relates to compounds disclosed herein and uses for managing inflammation resulting from traumatic brain injury or stroke.Type: ApplicationFiled: November 4, 2015Publication date: February 25, 2016Inventors: David B Guthrie, Mark A Lockwood, Dennis C. Liotta, Michael G Natchus, Donald G. Stein, Iqbal Sayeed
-
Publication number: 20160052958Abstract: The invention relates to a process for the purification of crude abiraterone acetate by treatment with polymer resins in aqueous solvent. The purified product is recovered by simple concentration and filtration.Type: ApplicationFiled: October 21, 2013Publication date: February 25, 2016Inventors: Marco Alpegiani, Tania Cristiano, Eugenio Cucchetti
-
Publication number: 20160052959Abstract: The disclosure provides compounds, methods, and kits for diagnosis, detection, screening, and imaging of a disease condition (e.g., infection, cancer, tumor, neoplasia), in vitro, ex vivo, and/or in vivo. Certain embodiments include administering a cationic steroid antimicrobial “CSA” or “ceragenin”), the CSA including a steroidal backbone and a heterocyclic ring separated from the steroidal backbone by at least 4 atoms (and up to 24 atoms or more), to a subject having or at risk of having a disease condition in an amount effective to diagnose, detect, screen for or image the disease condition in the subject.Type: ApplicationFiled: August 19, 2015Publication date: February 25, 2016Applicant: BRIGHAM YOUNG UNIVERSITYInventor: Paul B. Savage
-
Publication number: 20160052960Abstract: A process is disclosed wherein, using either 17a-(3-hydroxypropyl)-6p,7p;15p,16p-dimethylene-5p-androstane-3p,5,17p-triol (II) or 3?,5?iI???-6?,7?;15?,16?-dimethylene-5?,17?-pregnane-21,17-carbolactone (III) as starting material, through a single-step reaction it is obtained drospirenone (I), a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity, useful for preparing pharmaceutical compositions with contraceptive action.Type: ApplicationFiled: April 12, 2013Publication date: February 25, 2016Inventors: Roberto LENNA, Francesco BARBIERI, Maria Giovanna LUONI, Monica NOSEDA
-
Publication number: 20160052961Abstract: The present invention discloses methods of neutralizing apatite surfaces, for example during chromatography and before protein elution.Type: ApplicationFiled: November 4, 2015Publication date: February 25, 2016Inventors: Larry J. Cummings, Mark A. Snyder
-
Publication number: 20160052962Abstract: The present invention relates to a method for separating collagen from jellyfish by using radiation. More precisely, acid-soluble collagen and attelo collagen were prepared in this invention by using the method combining irradiation technique and chemical treatment. This method of the invention is expected to be useful for the separation of collagen from jellyfish with low costs but high yield.Type: ApplicationFiled: September 24, 2015Publication date: February 25, 2016Inventors: Youn-Mook LIM, Sung In JEONG, Hui-Jeong GWON, Jong Seok PARK, Young-Chang NHO, Phil-Hyun KANG, Young-Jin KIM
-
Publication number: 20160052963Abstract: A process for purification of a fatty acid binding proteins such as, e.g., Sm14 of Pichia pastoris or type-3 FABP protein of Fasciola hepatica. The process includes the steps of: (a) performing lysis of cells containing the fatty acid binding protein to obtain a lysate; (b) clarifying the lysate obtained in step (a) to obtain a clarified lysate; (c) loading the clarified lysate in a column containing an anion exchange resin; (d) eluting proteins from the column by pH changes in the column; and (e) separating contaminant proteins from the fatty acid binding protein by gel-filtration.Type: ApplicationFiled: October 19, 2015Publication date: February 25, 2016Inventors: Miriam TENDLER, Celso Raul Romero RAMOS, Andrew J.G. SIMPSON
-
Publication number: 20160052964Abstract: Certain embodiments are directed to compositions and methods of inhibiting a pathogenic bacterial infection involving ADAM10, specifically a method for treating pore-forming toxin-inducted pathology caused by exposure to staphylococcus in a subject, comprising administering an effective amount of a ADAM10 inhibitor to a patient. The methods include treating pneumonia or inhibiting disruption to epithelial barrier in a subject, having or at risk of developing staphylococcal infection.Type: ApplicationFiled: April 4, 2014Publication date: February 25, 2016Applicant: THE UNIVERSITY OF CHICAGOInventors: Juliane Bubeck WARDENBURG, Katherine SCHMALZER
-
Publication number: 20160052965Abstract: Molecular mimics of Smac are capable of modulating apoptosis through their interaction with cellular IAPs (inhibitor of apoptosis proteins). The mimetics are based on a monomer or dimer of the N-terminal tetrapeptide of IAP-binding proteins, such as Smac/DIABLO, Hid, Grim and Reaper, which interact with a specific surface groove of IAP. Also disclosed are methods of using these peptidomimetics for therapeutic purposes.Type: ApplicationFiled: October 15, 2015Publication date: February 25, 2016Applicant: TETRALOGIC BIRINAPANT UK LTD.Inventors: Stephen M. Condon, Matthew G. Laporte, Yijun Deng, Susan R. Rippin
-
Publication number: 20160052966Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.Type: ApplicationFiled: May 24, 2012Publication date: February 25, 2016Applicant: AMBRX, INC.Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun
-
Publication number: 20160052967Abstract: An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids.Type: ApplicationFiled: April 24, 2014Publication date: February 25, 2016Inventors: Rony SEGER, Eldar ZEHORAI
-
Publication number: 20160052968Abstract: A bone delivery conjugate having a structure selected from the group consisting of: A) X-Dn-Y-protein-Z; and B) Z-protein-Y-Dn-X, wherein X is absent or is an amino acid sequence of at least one amino acid; Y is absent or is an amino acid sequence of at least one amino acid; Z is absent or is an amino acid sequence of at least one amino acid; and Dn is a poly aspartate wherein n=10 to 16. Compositions comprising same and methods of use thereof.Type: ApplicationFiled: November 3, 2015Publication date: February 25, 2016Inventors: Philippe CRINE, Guy Boileau, Isabelle Lemire, Thomas P. Loisel
-
Publication number: 20160052969Abstract: An approach to synthesizing and assembling nanoparticles into discrete, size-tunable, pre-designed architectures is realized in a single synthetic/process step.Type: ApplicationFiled: November 3, 2015Publication date: February 25, 2016Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Nathaniel L. ROSI, Chun-Long Chen
-
Publication number: 20160052970Abstract: The present invention provides peptidomimetic macrocycles capable of regulating HIF1? and methods of using such macrocycles for the treatment of diseases.Type: ApplicationFiled: September 2, 2015Publication date: February 25, 2016Inventors: Vincent GUERLAVAIS, Noriyuki KAWAHATA, Huw M. NASH, Carl ELKIN, Eric FEYFANT
-
Publication number: 20160052971Abstract: Beta-hairpin peptidomimetics of the general formula (I), cyclo[P1-p2-p3-p4-p5-p6-p7-p8p9-p10-p11-p12-T1-T2], and pharmaceutically acceptable salts thereof, with P1 to P12, T1 and T2 being elements as defined in the description and the claims, have Gram-negative antimicrobial activity to e.g. inhibit the growth or to kill microorganisms such as Klebsiella pneumoniae and/or Acinetobacter baumannii and/or Escherichia coli. They can be used as medicaments to treat or prevent infections or as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials. These peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.Type: ApplicationFiled: March 28, 2014Publication date: February 25, 2016Applicant: POLYPHOR AGInventors: Daniel OBRECHT, Anatol LUTHER, Francesca BERNARDINI, Peter ZBINDEN
-
Publication number: 20160052972Abstract: The present invention relates to a compound of the formula (I): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection using the same.Type: ApplicationFiled: October 30, 2015Publication date: February 25, 2016Inventors: Zhuang SU, Zhennian HUANG, Zhengyu LONG, Suizhou YANG
-
Publication number: 20160052973Abstract: The present invention relates to the stabilisation of foot-and-mouth disease virus (FMDV) capsids, by specific substitution of amino acids in a specific region of FMDV VP2. The invention provides stabilised FMDV capsids and vaccines against FMD.Type: ApplicationFiled: March 25, 2014Publication date: February 25, 2016Applicant: Pirbright InstituteInventors: Abhay Kotecha, David Stuart, Elizabeth Fry, Robert Esnouf
-
Publication number: 20160052974Abstract: Novel polynucleotide and amino acids of Brachyspira hyodysenteriae are described. These sequences are useful for diagnosis of B. hyodysenteriae disease in animals and as a therapeutic treatment or prophylactic treatment of B. hyodysenteriae disease in animals. These sequences may also be useful for diagnostic and therapeutic and/or prophylactic treatment of diseases in animals caused by other Brachyspira species, including B. intermedia, B. suantatina, B. alvinipulli, B. aalborgi, B. innocens, B. murdochii, and B. pilosicoli.Type: ApplicationFiled: March 30, 2015Publication date: February 25, 2016Inventors: Matthew Bellgard, David J. Hampson, Tom La
-
Publication number: 20160052975Abstract: The inventive subject matter relates to a recombinant polypeptide construct comprising enterotoxigenic Escherichia coli fimbrial subunits. The recombinant polypeptide constructs comprise multiple subunits to the same or different ETEC fimbrial types. The constructs are useful for inclusion in immunogenic formulations for the inductin of immunity against entertoxigenic Escherichia coli. The inventive subject matter also relates to the use of the recombinant polypeptide constructs in induce anti-enterotoxigenic Escherichia coli.Type: ApplicationFiled: October 8, 2013Publication date: February 25, 2016Inventor: Stephen Savarino
-
Publication number: 20160052976Abstract: We described a novel system of targeted cell therapy with a protein toxin, such as anthrax toxin, that has been modified to re-direct it to a desired cell target instead of its natural cell target. The system can be used for, e.g., targeted killing of undesired cells in a population of cells, such as cancer or overly active immune system cells.Type: ApplicationFiled: February 18, 2015Publication date: February 25, 2016Inventors: Adva Mechaly, Andrew J. McCluskey, John R. Collier
-
Publication number: 20160052977Abstract: The present disclosure relates to novel pore-forming toxins of Type A C. perfringens and immunogenic compositions and vaccines thereof. The present disclosure further relates to methods and uses of treating or preventing enteric disease and assays for diagnosing enteric disease.Type: ApplicationFiled: August 21, 2015Publication date: February 25, 2016Inventors: John Prescott, Iman Mehdizadeh Gohari, Valeria Parreira Pinto
-
Publication number: 20160052978Abstract: The inventors provide a composition comprising an antimicrobial polypeptide comprising Blad or an active variant thereof for use in a method of treatment of the human or animal body by therapy or prophylaxis, such as for use in a method of treating or preventing an infection in or on a subject by a microorganism. Also provided is the use of a composition comprising an antimicrobial polypeptide comprising Blad or an active variant thereof to kill, or inhibit the growth of, a microorganism that is pathogenic to a human or an animal at a site that is not on or in the human or animal body.Type: ApplicationFiled: October 12, 2011Publication date: February 25, 2016Inventors: Alexandra Carreira, Ricardo Manuel De Seixas Boavida Ferreira, Sara Alexandra Valadas Da Silva Monteiro
-
Publication number: 20160052979Abstract: The present invention provides novel synthetic peptides (including the TZIP peptide) as oncogenic and genetic modulators, including genetics of viruses, as well as methods of making and using the same. These peptides are useful for inhibiting the proliferation of cancer cells characterized as having amplified c-MYC genes. The invention provides methods for the therapeutic uses of the peptides in the treatment of various cancers including small cell lung carcinoma, prostate cancer, lymphoma, brain tumors, colon cancer, bladder cancer, AML, malignant melanoma, mesothelioma, and cancers of head and neck. The peptides are also useful in the treatment of and prevention of transmission of HIV and treatment of expanded nucleotide repeat diseases, including certain currently untreatable and debilitating diseases.Type: ApplicationFiled: October 3, 2013Publication date: February 25, 2016Inventors: Edward M. JOHNSON, Dianne C. DANIEL
-
Publication number: 20160052980Abstract: Disclosed herein are human CRP40 fragments and polynucleotides encoding them. The CRP40 fragments and polynucleotides may be useful in the treatment of diseases associated with one or more of oxidative stress, mitochondrial dysfunction and abnormal protein folding, including various neurological disorders.Type: ApplicationFiled: April 4, 2014Publication date: February 25, 2016Inventors: Joseph GABRIELE, Ram MISHRA, Zdenek PRISTUPA
-
Publication number: 20160052981Abstract: Disclosed are methods of identifying an agent that modulates an NFAT regulator protein. One such method comprises contacting at least one test agent with recombinant cell comprising at least one NFAT regulator protein or fragment or derivative thereof, assessing the effect of the test agent on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, and identifying the test agent that has an effect on an activity, interaction, expression, or binding to the NFAT regulator protein or fragment or derivative thereof, whereby the identified test agent is characterized as an agent that modulates an NFAT regulator protein.Type: ApplicationFiled: August 21, 2015Publication date: February 25, 2016Applicant: CHILDREN'S MEDICAL CENTER CORPORATIONInventors: Anjana Rao, Stefan Feske, Patrick Hogan, Yousang Gwack
-
Publication number: 20160052982Abstract: The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.Type: ApplicationFiled: March 13, 2014Publication date: February 25, 2016Inventors: Charles Cohen, Krishna Kumar, Jamie Raudensky Doyle, Alan S. Kopin
-
Publication number: 20160052983Abstract: The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention.Type: ApplicationFiled: September 1, 2015Publication date: February 25, 2016Inventors: Juan Alvarez, Jean Chamoun, Heather C. Losey
-
Publication number: 20160052984Abstract: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.Type: ApplicationFiled: April 6, 2015Publication date: February 25, 2016Inventors: John WOZNEY, Howard Seeherman, Christopher Todd Brown
-
Publication number: 20160052985Abstract: The present invention relates to a compound selected in the group consisting of: a) a polypeptide consisting of the C-terminus amino acid sequence of the human Thymic stromal lymphopoietin (TSLP) long isoform (SEQ ID NO: 2), derivatives and fragments thereof; b) a polynucleotide coding for said polypeptide; d) a vector comprising said polynucleotide; c) a host cell genetically engineered expressing said polypeptide, or d) a TSLP long isoform (SEQ ID NO:2) antagonist for use in the treatment or/and prevention and/or diagnosis and/or monitoring of a disorder or pathology characterized by an inflammatory response.Type: ApplicationFiled: April 4, 2014Publication date: February 25, 2016Inventors: Maria RESCIGNO, Giuseppe PENNA, Katerina TSILINGIRI, Giulia FORNASA
-
Publication number: 20160052986Abstract: Genetically modified non-human animals comprising a human or humanized interleukin-7 (IL-7) gene. Cells, embryos, and non-human animals comprising a human or humanized IL-7 gene. Rodents that express human or humanized IL-7 protein. Genetically modified mice that comprise a human or humanized IL-7-encoding gene in their germline, wherein the human or humanized IL-7-encoding gene is under control of endogenous mouse IL-7 regulatory sequences.Type: ApplicationFiled: November 10, 2015Publication date: February 25, 2016Applicant: REGENERON PHARMACEUTICALS, INC.Inventor: Andrew J. Murphy
